UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM 6-K
__________________
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
January 9, 2018
Commission File Number: 001-38283
__________________________________
InflaRx N.V.
__________________________________
Winzerlaer Str. 2
07745 Jena, Germany
(+49) 3641 508180
(Address of principal executive offices)
__________________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F☒ Form 40-F☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):☐
On January 9, 2018, InflaRx N.V. ("InflaRx") issued a press release announcing the acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration, which will allow InflaRx to conduct a Phase IIb study to determine efficacy and safety of its lead product candidate IFX-1 in patients with moderate or severe Hidradenitis Suppurativa. A copy of this press release is attached hereto as Exhibit 99.1.
INCORPORATION BY REFERENCE
Exhibit 99.1 to this Report on Form 6-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jena, Germany, January 9, 2018.
INFLARX N.V. | ||
By: | /s/ Niels Riedemann | |
Name: Niels Riedemann | ||
Title: Chief Executive Officer |
EXHIBIT INDEX
Exhibit | Description of Exhibit |
99.1 | InflaRx N.V. Press Release dated January 9, 2018 |